Swallowing characterization of adult-onset Niemann-Pick, type C1 patients
- PMID: 38863022
- PMCID: PMC11165794
- DOI: 10.1186/s13023-024-03241-7
Swallowing characterization of adult-onset Niemann-Pick, type C1 patients
Abstract
Background: Niemann-Pick disease, type C1 (NPC1) is a rare lysosomal disorder with progressive neurological manifestations, historically recognized as a pediatric disease. However, awareness of the adult-onset (AO) subtype is increasing, often with non-specific symptoms leading to delayed and misdiagnosis. Dysphagia, commonly recognized as a clinical morbidity in NPC1, raises concerns for swallowing safety and aspiration risk. This study aims to characterize swallowing function in AO NPC1, addressing the gap in understanding and clinical management.
Methods: Fourteen AO NPC1 individuals in a prospective natural history study (NCT00344331) underwent comprehensive assessments, including history and physical examinations utilizing the NPC1 severity rating scale, videofluoroscopic swallowing studies with summary interpretive analysis, and cerebrospinal fluid (CSF) collection for biomarker evaluation at baseline visit. Descriptive statistics and multivariate statistical modeling were employed to analyze NPC1 disease covariates, along with the American Speech-Language-Hearing Association National Outcome Measure (ASHA-NOMS) and the NIH Penetration Aspiration Scale (NIH-PAS).
Results: Our cohort, comprised of 14 predominately female (n = 11, 78.6%) individuals, had an average age of 43.1 ± 16.7 years at the initial visit. Overall, our AO patients were able to swallow independently with no/minimal cueing, with 6 (43%) avoiding specific food items or requiring more time. Upon risk analysis of aspiration, the cohort demonstrated no obvious aspiration risk or laryngeal aspiration in 8 (57%), minimal risk with intermittent laryngeal penetration and retrograde excursion in 5(36%), and moderate risk (7%) in only one. Dietary modifications were recommended in 7 (50%), particularly for liquid viscosities (n = 6, 43%) rather than solids (n = 3, 21%). No significant correlations were identified between swallowing outcomes and NPC1-related parameters or CSF biomarkers.
Conclusion: Despite the heterogeneity in NPC1 presentation, the AO cohort displayed functional swallowing abilities with low aspiration risk with some participants still requiring some level of dietary modifications. This study emphasizes the importance of regular swallowing evaluations and management in AO NPC1 to address potential morbidities associated with dysphagia such as aspiration. These findings provide clinical recommendations for the assessment and management of the AO cohort, contributing to improved care for these individuals.
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
The authors have no competing interests to declare.
Figures



Similar articles
-
Phenotypic expression of swallowing function in Niemann-Pick disease type C1.Orphanet J Rare Dis. 2022 Sep 5;17(1):342. doi: 10.1186/s13023-022-02472-w. Orphanet J Rare Dis. 2022. PMID: 36064725 Free PMC article.
-
Association of Miglustat With Swallowing Outcomes in Niemann-Pick Disease, Type C1.JAMA Neurol. 2020 Dec 1;77(12):1564-1568. doi: 10.1001/jamaneurol.2020.3241. JAMA Neurol. 2020. PMID: 32897301 Free PMC article.
-
The videofluoroscopic swallowing study shows a sustained improvement of dysphagia in children with Niemann-Pick disease type C after therapy with miglustat.Am J Med Genet A. 2011 Mar;155A(3):540-7. doi: 10.1002/ajmg.a.33847. Epub 2011 Feb 22. Am J Med Genet A. 2011. PMID: 21344635
-
[Adult onset Niemann-Pick type C disease and psychosis: literature review].Encephale. 2013 Oct;39(5):315-9. doi: 10.1016/j.encep.2013.04.013. Epub 2013 Aug 5. Encephale. 2013. PMID: 23928063 Review. French.
-
Miglustat in Niemann-Pick disease type C patients: a review.Orphanet J Rare Dis. 2018 Aug 15;13(1):140. doi: 10.1186/s13023-018-0844-0. Orphanet J Rare Dis. 2018. PMID: 30111334 Free PMC article. Review.
Cited by
-
Efficacy results from a 12-month double-blind randomized trial of arimoclomol for treatment of Niemann-Pick disease type C (NPC): Presenting a rescored 4-domain NPC Clinical Severity Scale.Mol Genet Metab Rep. 2025 May 28;43:101233. doi: 10.1016/j.ymgmr.2025.101233. eCollection 2025 Jun. Mol Genet Metab Rep. 2025. PMID: 40520915 Free PMC article.
References
-
- Wassif CA, Cross JL, Iben J, Sanchez-Pulido L, Cougnoux A, Platt FM, et al. High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genet Med. 2016;18(1):41–48. doi: 10.1038/gim.2015.25. - DOI - PMC - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous